GenMark Diagnostics Accounts Payable

GenMark Diagnostics (GNMK) currently reports a accounts payable of $23M as of December 2020. That compares with $12M in the prior-year period — up 88.4% year over year. Use the charts on this page to explore GenMark Diagnostics's accounts payable history and peer comparisons.

GenMark Diagnostics's accounts payable increased from $12M to $23M — a 88.4% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GenMark Diagnostics reported $23M in accounts payable as of December 2020. That compares with $12M in the prior-year period — up 88.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for GenMark Diagnostics, and consider following GNMK for alerts when major investors trade the stock.

GenMark Diagnostics is classified in the Healthcare sector. On accounts payable, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GNMK with unrelated industries.